References
- Jabbour E, Lipton JH. A Critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Clin Lymphoma Myeloma Leuk. 2013;13:646–656.
- Wang YL, Bagg A, Pear W, et al. Chronic myelogenous leukemia: laboratory diagnosis and monitoring. Genes Chromosomes Cancer. 2001;32:97–111.
- Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94:107–121.
- Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program. 2009;477–487. doi: 1asheducatio/asheducation-2009.1.477.
- Castagnetti F, Testoni N, Luatti S, et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML working party analysis. J Clin Oncol. 2010;28:2748–2754.
- Baccarani M, Soverini S, Benedittis CD. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor. Am Soc Clin Oncol Educ Book. 2014;167–175. doi: 10.14694/EdBook_AM.2014.34.167.
- Tohami T, Nagler A, Amariglio N. Laboratory tools for diagnosis and monitoring response in patients with chronic myeloid leukemia. Imaj. 2012;14:502–507.
- Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. 2013;122:872–884.
- Vaidya S, Vundinti BR, Shanmukhaiah C, et al. Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor. PLoS One. 2015;28:14.
- Aggoune D, Tosca L, Sorel N, et al. Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors. Oncoscience. 2014;1:57–68.
- Bozkurt S, Uz B, Buyukasik Y, et al. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia. Med Oncol. 2013;30:443.
- Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118:6760–6768.
- Kim TD, Türkmen S, Schwarz S, et al. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica. 2010;95:582–588.
- Shah B, Gajendra S, Gupta R, et al. Novel cytogenetic aberrations in a patient of chronic myeloid leukemia with blast crisis. J Clin Diagn Res. 2015;9:5–6.
- Gorusu M, Benn P, Li Z, et al. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet. 2007;173:97–106.
- Savasoglu K, Payzin KB, Ozdemirkiran F, et al. Effectiveness of quantitative real time PCR in long term follow up of chronic myeloid leukemia patients. J Coll Physicians Surg Pak. 2015;25:568–572.
- Eide CA, Hare TO. Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep. 2015;10:158–166.
- Bode KMG, Heinze B. On the power of additional and complex chromosomal aberrations in CML. Curr Genomics. 2012;13:471–476.
- Rohon P, Faber E, Divoka M, et al. A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157:181–188.
- Eskazan AE, Soysal T. Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients? Leukemia Res. 2011;35:5–6.
- Hughes T, Deininger M, Hpchhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.